- Home
- MRT vs EDIT Comparison
MRT vs EDIT Comparison
Compare MRT & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRT | EDIT |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.5M | 202.1M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | MRT | EDIT |
|---|---|---|
| Price | $2.00 | $2.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $6.00 | $4.50 |
| AVG Volume (30 Days) | 58.5K | ★ 2.0M |
| Earning Date | 08-08-2018 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $24,577,378.00 | ★ $46,383,000.00 |
| Revenue This Year | $84.11 | N/A |
| Revenue Next Year | $118.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 29.67 | N/A |
| 52 Week Low | $1.97 | $0.91 |
| 52 Week High | $3.79 | $4.54 |
Technical Indicators
Market Signals| Indicator | MRT | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 38.37 | 44.03 |
| Support Level | $2.06 | $2.05 |
| Resistance Level | $2.20 | $2.17 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 11.76 | 24.71 |
Price Performance
Historical ComparisonAbout MRT Marti Technologies Inc.
Marti Technologies Inc is a mobility app, offering multiple transportation services to its riders. Marti operates a ride-hailing service that matches riders with car, motorcycle, and taxi drivers, and operates a large fleet of rental e-mopeds, e-bikes, and e-scooters. All of Marti's offerings are serviced by proprietary software systems and IoT infrastructure.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.